According to NICE guidance (NG28), these medications are considered at specific stages of type 2 diabetes treatment, depending on individual factors including HbA1c levels, cardiovascular risk, kidney function, and weight management needs
10.1038/s41598-021-85662-z 63 KimH
As of 2026, BPC-157 is not approved by any regulatory authority (FDA, EMA, ANSM)
Because it is an injection, injection-site reactions like swelling, pain, or redness may also occur
This is documented pharmacological tolerance, and it affects most people to some degree
Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity